Recent Announcements

Institute for Clinical and Economic Review’s final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients

--Final Report and Meeting Summary reviews evidence on 11 targeted immunomodulator drugs, including two currently under FDA review: sarilumab and baricitinib; highlights actions for payers, manufacturers, clinical societies, and other stakeholders to improve patient care while controlling costs--

Read More